Skip to main content

Table 4 Subgroup analysis of SARS-CoV-2 RNA recurrent positive

From: The relationship between SARS-COV-2 RNA positive duration and the risk of recurrent positive

Subgroup No. of participants OR 95% CI P value P for interaction
Sex
 Female 202 1.05 1.01–1.09 0.011 0.789
 Male 209 1.06 1.01–1.10 0.018
Age (year)
 < 18 14 - - - -
 ≥ 18 397 1.05 1.02–1.08 0.001
BMI (kg/m2)
 < 24 267 1.04 1.00–1.07 0.026 0.350
 ≥ 24 144 1.07 1.02–1.12 0.007
Clinical type
 Mild-to-moderate infection 349 1.05 1.02–1.09  < 0.001 0.080
 Severe-to-critical infection 62 0.94 0.84–1.05 0.289
White blood cell count (tertile)
 Low (2.70–4.76) 134 1.09 1.04–1.15 0.001 0.176
 Middle (4.80–6.30) 140 1.03 0.99–1.07 0.144
 High (6.31–36.10) 137 1.05 0.99–1.10 0.115
Neutrophil count (tertile)
 Low (0.47–2.53) 133 1.10 1.03–1.17 0.004 0.223
 Middle (2.55–3.65) 141 1.03 0.99–1.08 0.176
 High (3.66–13.45) 137 1.07 1.01–1.13 0.023
Neutrophil percentage (tertile)
 Low (7.2–53.7) 137 1.00 0.95–1.06 0.899 0.112
 Middle (53.8–64.0) 137 1.09 1.02–1.17 0.011
 High (64.1–94.9) 137 1.06 1.00–1.13 0.052
Lymphocyte count (tertile)
 Low (0.16–1.27) 137 1.04 0.98–1.10 0.172 0.023
 Middle (1.28–1.78) 132 1.14 1.06–1.23 0.001
 High (1.80–8.22) 142 1.02 0.97–1.07 0.382
Lymphocyte percentage (tertile)
 Low (4.4–24.9) 137 1.04 0.98–1.11 0.153 0.738
 Middle (25.0–33.6) 137 1.06 1.01–1.12 0.015
 High (33.7–84.0) 137 1.03 0.98–1.09 0.193
Monocyte count (tertile)
 Low (0.03–0.38) 135 1.20 1.08–1.32 0.001 0.002
 Middle (0.39–0.53) 133 1.03 0.96–1.11 0.343
 High (0.54–2.66) 143 1.00 0.94–1.06 0.989
Monocyte percentage (tertile)
 Low (0.3–7.1) 134 1.15 1.05–1.26 0.003 0.036
 Middle (7.2–9.7) 138 1.10 1.01–1.21 0.028
 High (9.8–41.7) 139 1.01 0.94–1.08 0.847
Hemoglobin (tertile)
 Low (71–122) 136 1.09 1.01–1.17 0.018 0.673
 Middle (122–137) 133 1.05 0.99–1.11 0.123
 High (137–297) 142 1.06 1.00–1.13 0.035
Platelet count (tertile)
 Low (66–180) 137 1.04 0.98–1.11 0.191 0.871
 Middle (180–226) 137 1.05 1.00–1.11 0.032
 High (226–577) 137 1.06 1.01–1.12 0.021
Chronic diseases
 No 262 1.04 1.00–1.07 0.031 0.181
 Yes 149 1.08 1.02–1.13 0.004
Hypertension
 No 335 1.04 1.01–1.07 0.019 0.008
 Yes 76 1.17 1.06–1.29 0.002
Diabetes
 No 375 1.05 1.02–1.08 0.001 -
 Yes 36 - - -
Chronic pulmonary disease
 No 390 1.05 1.02–1.08 0.001 -
 Yes 21 - - -
Coronary heart disease
 No 393 1.05 1.02–1.07 0.001 -
 Yes 18 - - -
Chronic kidney disease
 No 406 1.05 1.02–1.08 0.001 -
 Yes 5 - - -
Chronic liver disease
 No 365 1.05 1.02–1.08 0.001 -
 Yes 46 - - -
Malignant tumor
 No 404 1.05 1.02–1.08 < 0.001 -
 Yes 7 - - -
No. of antiviral drugs
 0 78 1.10 0.97–1.25 0.133 0.688
 1 178 1.05 1.00–1.10 0.030
 ≥ 2 155 1.04 1.00–1.08 0.037
Glucocorticoid
 No 366 1.04 1.01–1.06 0.005 0.005
 Yes 45 1.78 0.80–3.94 0.158
  1. Clinical type, routine blood test and treatment were the conditions of the previous discharge
  2. Because of the small number of cases in the Age and underlying disease (Diabetes, chronic pulmonary disease, coronary heart disease, chronic kidney disease, chronic liver disease, malignant tumor) subgroups, it is failed to calculate the effect value, confidence interval and interaction P value
  3. Because 1 patient is chronic lymphoblastic leukemia, there are abnormal values at the maximum of white blood cell count, lymphocyte count and lymphocyte percentage
  4. CI confidence interval, OR odd ratio
\